Susceptibility of lung cancer patients to COVID-19: A review of the pandemic data from multiple nationalities

Autor:	Aline da Rocha Matos, Gabriela Ribeiro Silva, Etel Rodrigues Pereira Gimba, Ana Emília Goulart Lemos
Rok vydání:	2021
Předmět:	Pulmonary and Respiratory Medicine Risk medicine.medical_specialty 2019-20 coronavirus outbreak Internationality Lung Neoplasms Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Mini Review severity Comorbidity Severity of Illness Index SARS‐CoV‐2 Disease severity COVID‐19 Pandemic medicine Prevalence Humans Intensive care medicine Lung cancer RC254-282 Geography business.industry SARS-CoV-2 Treatment delay Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens COVID-19 Immunosuppression General Medicine medicine.disease mortality lung cancer Treatment Outcome Oncology Disease Susceptibility business
Zdroj:	Thoracic Cancer Thoracic Cancer, Vol 12, Iss 20, Pp 2637-2647 (2021)
ISSN:	1759-7714
Popis:	Several studies have highlighted that cancer patients tend to be more susceptible to develop severe infection and to die from COVID‐19. Certain medical conditions such as immunosuppression, presence of comorbidities, and underlying pulmonary damage are possible determinants of disease severity, especially in lung cancer patients. While recent studies have shown that lung cancer is one of the most prevalent tumor types among COVID‐19 cancer patients, we still have an incomplete view of how data from several countries work as a whole. The aim of this review was to investigate COVID‐19 prevalence in lung cancer patient cohorts and their probability to develop severe illness and death when compared to nonlung cancer patients from multiple nationalities, including countries that have been the epicenters of the pandemic. We also focus on some intrinsic lung cancer features that might influence COVID‐19 outcomes. An integrative view of the susceptibility of lung cancer patients might be especially relevant to assist physicians in evaluating the risks of COVID‐19 in these patients, and to foster better decisions on treatment delay. Lung cancer is the most prevalent among COVID‐19 cancer patients in almost all the analyzed cohorts. Lung cancer patients (LCPs) also have an increased probability of death from COVID‐19 when compared to nonlung cancer patients (NLCPs) in different countries. The probability measure could be used to evaluate the susceptibility of LCPs to develop severe COVID‐19 outcomes. The data integrative view might assist physicians in evaluating the risks of COVID‐19 in LCPs, ultimately preventing deaths.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23c5bdf52a132777d7086a3da1b6971 https://pubmed.ncbi.nlm.nih.gov/34435733 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.